Galmed Pharmaceuticals Ltd [NASDAQ: GLMD] traded at a high on N/A, posting a 6.37 gain after which it closed the day’ session at $1.67.
The results of the trading session contributed to over 60168077 shares changing hands. Over the past one week, the price volatility of Galmed Pharmaceuticals Ltd stands at 19.94% while the volatility over the past one month is 14.73%.
The market cap for GLMD stock reached $3.78 million, with 2.26 million shares outstanding and 2.22 million shares in the current float. Compared to the average trading volume of 867.59K shares, GLMD reached a trading volume of 60168077 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Galmed Pharmaceuticals Ltd [GLMD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GLMD shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GLMD stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR have made an estimate for Galmed Pharmaceuticals Ltd shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 22, 2020. While these analysts kept the previous recommendation, Craig Hallum raised their target price to Buy. The new note on the price target was released on February 04, 2020, representing the official price target for Galmed Pharmaceuticals Ltd stock. Previously, the target price had yet another raise from $9 to $14, while Cantor Fitzgerald kept a Overweight rating on GLMD stock.
The Average True Range (ATR) for Galmed Pharmaceuticals Ltd is set at 0.25 The Price to Book ratio for the last quarter was 0.17, with the Price to Cash per share for the same quarter was set at 6.83.
How has GLMD stock performed recently?
Galmed Pharmaceuticals Ltd [GLMD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.29. With this latest performance, GLMD shares dropped by -0.60% in over the last four-week period, additionally sinking by -63.22% over the last 6 months – not to mention a drop of -65.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GLMD stock in for the last two-week period is set at 53.16, with the RSI for the last a single of trading hit 61.90, and the three-weeks RSI is set at 48.42 for Galmed Pharmaceuticals Ltd [GLMD]. The present Moving Average for the last 50 days of trading for this stock 1.8531, while it was recorded at 1.5900 for the last single week of trading, and 3.2300 for the last 200 days.
Galmed Pharmaceuticals Ltd [GLMD]: Deeper insight into the fundamentals
Galmed Pharmaceuticals Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.42 and a Current Ratio set at 7.42.
Earnings analysis for Galmed Pharmaceuticals Ltd [GLMD]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GLMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Galmed Pharmaceuticals Ltd go to 62.35%.
Insider trade positions for Galmed Pharmaceuticals Ltd [GLMD]
There are presently around $2.06%, or 2.12%% of GLMD stock, in the hands of institutional investors.
